Portal de Periódicos da CAPES

Understanding the role of natural killer cell receptors and their human leukocyte antigen ligands in multiple sclerosis

2009; Wiley; Volume: 65; Issue: 6 Linguagem: Inglês

10.1002/ana.21747

1531-8249

Elizabeth Trachtenberg,

Reproductive System and Pregnancy

Annals of NeurologyVolume 65, Issue 6 p. 626-628 Editorial Understanding the role of natural killer cell receptors and their human leukocyte antigen ligands in multiple sclerosis† Elizabeth A. Trachtenberg MS, PhD, D(ABHI), Elizabeth A. Trachtenberg MS, PhD, D(ABHI) Children's Hospital & Research Center Oakland (CHRCO)Search for more papers by this author Elizabeth A. Trachtenberg MS, PhD, D(ABHI), Elizabeth A. Trachtenberg MS, PhD, D(ABHI) Children's Hospital & Research Center Oakland (CHRCO)Search for more papers by this author First published: 11 May 2009 https://doi.org/10.1002/ana.21747Citations: 13 † Potential conflict of interest: Nothing to report. Read the full textAboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Share a linkShare onEmailFacebookTwitterLinkedInRedditWechat References 1 Vivier E, Tomasello E, Baratin M, et al. Functions of natural killer cells. Nat Immunol 2008; 9: 503–510. 2 De Rham C, Ferrari-Lacraz S, Jendly S, et al. The proinflammatory cytokines IL-2, IL-15 and IL-21 modulate the repertoire of mature human natural killer cell receptors. Arthritis Res Ther 2007; 9: 1–15. 3 Parham P. MHC class I molecules and KIRs in human history, health and survival. Nat Rev 2005; 5: 201–214. 4 Takahashi K, Aranami T, Endoh M, et al. The regulatory role of natural killer cells in multiple sclerosis. Brain 2004; 127: 1917–1927. 5 Morandi B, Bramanti P, Bonaccorsi I, et al. Role of natural killer cells in the pathogenesis and progression of multiple sclerosis. Pharmacol Res 2008; 57: 1–5. 6 Lanier LL. Up on the tightrope: natural killer cell activation and inhibition. Nat Immunol 2008; 9: 495–502. 7 Chan AT, Kollnberger SD, Wedderburn LR, Bowness P. Expansion and enhanced survival of natural killer cells expressing the killer immunoglobulin-like receptor KIR3DL2 in spondylarthritis. Arthritis Rheum 2005; 52: 3586–3595. 8 Carrington M, Martin MP. The impact of variation at the KIR gene cluster on human disease. Curr Top Microbiol Immunol 2006; 298: 225–257. 9 Karlsen TH, Boberg KM, Olsson M, et al. Particular genetic variants of ligands for natural killer cell receptors may contribute to the HLA associated risk of primary sclerosing cholangitis. J Hepatol 2007; 46: 899–906. 10 van der Slik AR, Roeleman PC, Verduijn W, et al. KIR in type 1 diabetes: disparate distribution of activating and inhibitory natural killer cell receptors in patients versus HLA-matched control subjects. Diabetes 2003; 52: 2639–2642. 11 Williams F, Meenagh A, Sleator C, et al. Activating killer cell immunoglobulin-like receptor gene KIR2DS1 is associated with psoriatic arthritis. Hum Immunol 2005; 66: 836–841. 12 Yen JH, Lin CH, Tsai WC, et al. Killer cell immunoglobulin-like receptor gene's repertoire in rheumatoid arthritis. Scand J Rheumatol 2006; 35: 124–127. 13 Lopez-Larrea C, Blanco-Gelaz MA, Torre-Alonso JC, et al. Contribution of KIR3DL1/3DS1 to ankylosing spondylitis in human leukocyte antigen-B27 Caucasian populations. Arthritis Res Ther 2006; 8: R101. 14 Hollenbach JA, Ladner MB, Saeturn K, et al. Susceptibility to Crohn's disease is mediated by KIR2DL2/KIR2DL3 heterozygosity and the HLAC ligand. Immunogenetics (submitted). 15 Lorentzen AR, Karlesen TH, Olsson M, et al. Killer immunoglobulin-like receptor ligand HLA-Bw4 protects against multiple sclerosis. Ann Neurol 2009; 65: 658–666. 16 Kim S, Sunwoo JB, Yang L, et al. HLA alleles determine differences in human natural killer cell responsiveness and potency. Proc Natl Acad Sci U S A 2008; 105: 3053–3058. 17 Kim S, Poursine-Laurent J, Truscott SM, et al. Licensing of natural killer cells by host major histocompatibility complex class I molecules. Nature 2005; 436: 709–713. 18 Flores-Villanueva PO, Yunis EJ, Delgado JC, et al. Control of HIV-1 viremia and protection from AIDS are associated with HLA-Bw4 homozygosity. Proc Natl Acad Sci U S A 2001; 98: 5140–5145. 19 Carr WH, Pando MJ, Parham P. KIR3DL1 polymorphisms that affect NK cell inhibition by HLA-Bw4 ligand. J Immunol 2005; 175: 5222–5229. 20 Yawata M, Yawata N, Draghi M, et al. Roles for HLA and KIR polymorphisms in natural killer cell repertoire selection and modulation of effector function. J Exp Med 2006; 203: 633–645. 21 O'Connor GM, Guinan KJ, Cunningham RT, et al. Functional polymorphism of the KIR3DL1/S1 receptor on human NK cells. J Immunol 2007; 178: 235–241. 22 Martin MP, Qi Y, Gao X, et al. Innate partnership of HLA-B and KIR3DL1 subtypes against HIV-1. Nat Genet 2007; 39: 708–710. 23 Boyington JC, Sun PD. A structural perspective on MHC class I recognition by killer cell immunoglobulin-like receptors. Mol Immunol 2002; 38: 1007–1021. 24 Moesta AK, Norman PJ, Yawata M, et al. Synergistic polymorphism at two positions distal to the ligand-binding site makes KIR2DL2 a stronger receptor for HLA-C than KIR2DL3. J Immunol 2008; 180: 3969–3979. 25 Maxwell LD, Wallace A, Middleton D, Curran MD. A common KIR2DS4 deletion variant in the human that predicts a soluble KIR molecule analogous to the KIR1D molecule observed in the rhesus monkey. Tissue Antigens 2002; 60: 254–258. 26 Middleton D, Gonzalez A, Gilmore PM. Studies on the expression of the deleted KIR2DS4*003 gene product and distribution of KIR2DS4 deleted and nondeleted versions in different populations. Hum Immunol 2007; 68: 128–134. 27 Morse RH, Seguin R, McCrea EL, Antel JP. NK cell-mediated lysis of autologous human oligodendrocytes. J Neuroimmunol 2001; 116: 107–115. 28 Antel JP, McCrea E, Ladiwala U, et al. Non-MHC-restricted cell-mediated lysis of human oligodendrocytes in vitro: relation with CD56 expression. J Immunol 1998; 160: 1606–1611. Citing Literature Volume65, Issue6June 2009Pages 626-628 ReferencesRelatedInformation